AVGO vs PFE: Which Is the Better Buy?

Side-by-side comparison of Broadcom Inc. and Pfizer Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-05.
Broadcom Inc. ยท Technology
$371.59
-45.0% upside to fair value
Grade C High Quality
VS
Pfizer Inc. ยท Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value (+28.6%). PFE trades at a lower forward P/E (19.3x). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric AVGO PFE
Current Price $371.59 $26.33
Fair Value Estimate $204.37 $33.85
Upside to Fair Value -45.0% +28.6%
Market Cap $1,761.8B $149.8B
Forward P/E 70.7x 19.3x
EV / EBITDA 46.7x 12.9x
Price / Sales 25.9x 2.4x
Price / FCF 61.1x 16.5x
Revenue Growth YoY +7.2% -1.2%
Gross Margin 67.1% 70.3%
Operating Margin 40.9% 24.7%
Return on Equity 32.9% 8.7%
Dividend Yield 0% 0%
FCF Yield 1.64% 6.06%
Analyst Consensus Strong Buy Hold
Investment Thesis
AVGO โ€” Broadcom Inc.
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a strong competitive moat driven by scale, diversification, and aggressive M&A under CEO Hock E. Tan. The company has demonstrated robust revenue growth, particularly in semiconductor solutions and infrastructure software segments, with a 25% year-over-year increase recently and a five-yโ€ฆ
PFE โ€” Pfizer Inc.
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating maโ€ฆ
Accumulation Zones
Metric AVGO PFE
Zone Low $153.28 $25.39
Zone High $173.71 $28.77
In Buy Zone? No Yes
โ† AVGO Research    PFE Research โ†’    All Research